Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

Study Identifier
P17-132
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

Study Details

Medical Condition
  • Blood Cancer - Chronic Lymphocytic Leukemia (CLL)
  • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.

    Study Locations

    Location
    Status
    Location
    Universitaetsklinikum St. Poelten /ID# 221152
    Sankt Pölten, Lower Austria, Austria, 3100
    Status
    Recruiting
    Location
    Medizinische Universitaet Graz /ID# 221155
    Graz, Styria, Austria, 8010
    Status
    Completed
    Location
    Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153
    Salzburg, Austria, 5020
    Status
    Active, Not Recruiting
    Location
    Hanusch Krankenhaus /ID# 221151
    Vienna, Austria, 1140
    Status
    Completed
    Location
    Stauferklinikum Schwaebisch Gmuend /ID# 201518
    Mutlangen, Baden-Wurttemberg, Germany, 73557
    Status
    Completed
    Location
    Onkologische Praxis /ID# 201545
    Stuttgart, Baden-Wurttemberg, Germany, 70174
    Status
    Completed
    Showing {first} - {last} of {total} Results